5 days ago
1
Nemes Laszlo/iStock via Getty Images
- Guardant Health (NASDAQ:GH) lost ~9% in the premarket on Thursday after the company shared data from a clinical trial for its latest colorectal cancer (CRC) screening algorithm (V2) used in its Shield blood test.
- The study, an extension of Guardant’s registrational
English (US) ·